Literature DB >> 28300540

Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.

Fabiana Marnetto1, Paola Valentino2, Marzia Caldano3, Antonio Bertolotto4.   

Abstract

The presence of KIR4.1 antibodies has been proposed to be a characteristic of Multiple Sclerosis (MS). This could have a significant impact on disease management. However, the validation of the initial findings has failed till date. Conflicting results have been attributed to difficulties in isolating the lower-glycosylated (LG) KIR4.1 expressed in oligodendrocytes, the putative target antigen of autoantibodies. The aim of this study is to verify the presence of KIR4.1 antibodies in MS patients, by independently replicating the originally-described procedure. Assay procedure consisted of KIR4.1 expression in HEK293 cells, 3-step elution to isolate LG-KIR4.1 in elution fraction 3, and ELISA. Sera of 48 MS patients and 46 HCs were studied in 21 working sessions. In a preliminary analysis, we observed different KIR4.1 antibody levels between MS patients and Healthy Controls (HCs). However, a high variability across working sessions was observed and the sensitivity of the assay was very low. Thus, stringent criteria were established in order to identify working sessions in which the pure LG-KIR4.1 was isolated. As per these criteria, we detected LG-KIR4.1 antibodies in 28% of MS patients and 5% of HCs. Unlike previous findings, this study is in agreement with the original report. We propose further efforts be made towards the development of a uniform method to establish the detection of KIR4.1 antibodies in MS patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acceptance criteria; Antigen purification; ELISA; KIR4.1 antibodies; Multiple sclerosis

Mesh:

Substances:

Year:  2017        PMID: 28300540     DOI: 10.1016/j.jim.2017.03.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

Review 1.  An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.

Authors:  Marwa Kaisey; Ghazal Lashgari; Justyna Fert-Bober; Daniel Ontaneda; Andrew J Solomon; Nancy L Sicotte
Journal:  Curr Neurol Neurosci Rep       Date:  2022-10-21       Impact factor: 6.030

2.  G protein-coupled receptors differentially regulate glycosylation and activity of the inwardly rectifying potassium channel Kir7.1.

Authors:  Sheridan J Carrington; Ciria C Hernandez; Daniel R Swale; Oluwatosin A Aluko; Jerod S Denton; Roger D Cone
Journal:  J Biol Chem       Date:  2018-09-26       Impact factor: 5.157

Review 3.  Ion channels as therapeutic antibody targets.

Authors:  Catherine J Hutchings; Paul Colussi; Theodore G Clark
Journal:  MAbs       Date:  2018-12-10       Impact factor: 5.857

Review 4.  Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.

Authors:  Michie Imamura; Osamu Higuchi; Yasuhiro Maeda; Akihiro Mukaino; Mitsuharu Ueda; Hidenori Matsuo; Shunya Nakane
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

Review 5.  Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease.

Authors:  Joseph A Lopez; Martina Denkova; Sudarshini Ramanathan; Russell C Dale; Fabienne Brilot
Journal:  Clin Transl Immunology       Date:  2021-07-26

Review 6.  Nutritional ketosis as an intervention to relieve astrogliosis: Possible therapeutic applications in the treatment of neurodegenerative and neuroprogressive disorders.

Authors:  Gerwyn Morris; Michael Maes; Michael Berk; André F Carvalho; Basant K Puri
Journal:  Eur Psychiatry       Date:  2020-01-31       Impact factor: 5.361

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.